TITLE:
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

CONDITION:
Colorectal Cancer

INTERVENTION:
Erlotinib (aka Tarceva or OSI-774)

SUMMARY:

      The purpose of this study is test the safety of Tarceva, find the best dose, and see what
      effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will
      be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without
      Bevacizumab.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Subjects must fulfill all of the following criteria to be eligible for study entry:

          -  Signed informed consent

          -  At least 18 years of age

          -  Histologically confirmed metastatic colorectal adenocarcinoma of the colon or rectum

        Resected or biopsied primary tumors or metastatic site will serve as the basis for
        histologic confirmation.

          -  Measurable disease (defined as at least one dimension >2 cm [>1 cm on spiral CT
             scans])

          -  ECOG performance status of 0 or 1

          -  Life expectancy >3 months

          -  Use of an effective means of contraception in men and in women of childbearing
             potential

          -  Ability to comply with study and follow-up procedures
      
